Stay updated on CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page.

Latest updates to the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe NIH-wide announcement about website updates and the terminology transition from “Artificial Intelligence” to “Super Intelligence” is no longer shown above the study-record error page.SummaryDifference1%

- Check17 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice appears above the page, announcing an NIH website transition and saying that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov version as v3.7.2 instead of v3.7.1. The page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record, indicating access to the NCT03463681 entry is blocked. The site chrome (header, navigation, and footer) remains visible, signaling a site-level access problem rather than updated study content.SummaryDifference17%

Stay in the know with updates to CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page.